DNA RNA and Cells

05 Dec 2016 Kite Pharma Initiates Rolling Submission of U.S. Biologics License Application (BLA) for KTE-C19, its Investigational anti-CD19 CAR-T Therapy, for the Treatment of Patients with Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma (NHL)
04 Dec 2016 In Clinical Trials, CAR T Cell Immunotherapy Continues to Yield Complete Responses in Children & Young Adults with Relapsed and Refractory Leukemia
04 Dec 2016 Spark Therapeutics and Pfizer Present Updated Preliminary Data from Hemophilia B Phase 1/2 Trial Suggesting Consistent and Sustained Levels of Factor IX Activity at Annual ASH Meeting
04 Dec 2016 Atara Bio Announces Results from Ongoing Phase 2 Trial of Allogeneic Cytomegalovirus (CMV)-specific Cytotoxic T Lymphocytes (CTL) at the American Society of Hematology (ASH) Annual Meeting 2016
04 Dec 2016 uniQure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients with Severe Hemophilia B
04 Dec 2016 Alnylam Reports Positive Initial Clinical Activity Results for Givosiran (ALN-AS1), an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias
04 Dec 2016 bluebird bio Presents New Data from HGB-205 Study of LentiGlobinTM Drug Product in Patients with Transfusion-Dependent β-Thalassemia (TDT) and Severe Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
04 Dec 2016 Bellicum Announces Updated Clinical Data from BPX-501 Study in Children with Primary Immune Deficiencies and Hemoglobinopathies
04 Dec 2016 Alnylam Reports Positive Interim Phase 1 Results for Fitusiran in Hemophilia A and B Patients with Inhibitors
04 Dec 2016 Juno Therapeutics Announces Complete Response and Corresponding Early Survival Data for JCAR014 in Patients with Ibrutinib-Refractory CLL
04 Dec 2016 Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL
01 Dec 2016 Sorrento's TNK Therapeutics Provides Progress Update for its Anti-CD38 and CD123 CAR-T Programs for Treatment of Hematological Malignancies
01 Dec 2016 bluebird bio Announces Interim Phase 1 Dose Escalation Data for its Anti-BCMA CAR T Product Candidate in Patients with Relapsed/Refractory Multiple Myeloma
30 Nov 2016 Arrowhead Pharmaceuticals Focuses Resources on Subcutaneous and Extra-Hepatic RNAi Therapeutics
29 Nov 2016 VBL Therapeutics Announces Overall Survival Data for VB-111 Monotherapy in Phase 2 Study for Recurrent Thyroid Cancer
29 Nov 2016 Gemphire Therapeutics Enrolls First Patients in the ROYAL-1 Trial Investigating Gemcabene in Hypercholesterolemia
23 Nov 2016 Juno Therapeutics Places JCAR015 Phase II ROCKET Trial on Clinical Hold
23 Nov 2016 NantKwest Announces Landmark Study Published on high affinity haNK Cell Therapy in the Journal Oncotarget
22 Nov 2016 Tocagen Presents Updated Clinical and Preclinical Data at Scientific Meetings
22 Nov 2016 Clinical and Pre-Clinical Data on Mustang Bio’s MB-101 (IL13Rα2-specific CAR T cells) for the Treatment of Glioblastoma (GBM) Presented at the 21st Annual Meeting and Education Day of the Society for Neuro-Oncology
22 Nov 2016 Viralytics’ CAVATAK in Combination with KEYTRUDA Provides Promising Results in Advanced Melanoma from the CAPRA 1b study
21 Nov 2016 Celyad Announces the Approval to Initiate Its NKR-2 CAR-T Clinical Trial in Belgium
17 Nov 2016 ZIOPHARM Announces Clinical Data on Ad-RTS-hIL-12 Demonstrates Survival Benefits in Patients with Recurrent Brain Cancer
16 Nov 2016 Agilis Biotherapeutics Announces First Patient Treated in Phase IIb Clinical Study of Gene Therapy for AADC Deficiency
16 Nov 2016 Cellectis Announces Successful cGMP Manufacturing for Second Product Candidate: UCART123

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing